Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis.
Compston JE, Audran M, Avouac B, Bouvenot G, Devogelaer J, Eastell R, Fabris F, Gennari C, Jones EA, Kaufman JM, Lemmel E, Mazzuoli G, Reid DM, Ringe JD, Vanhaelst L, Ziegler R, Reginster JY. Compston JE, et al. Among authors: eastell r. Calcif Tissue Int. 1996 Nov;59(5):323-7. doi: 10.1007/s002239900134. Calcif Tissue Int. 1996. PMID: 8849396 No abstract available.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Reid DM, et al. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6. Lancet. 2009. PMID: 19362675 Clinical Trial.
Management of male osteoporosis: report of the UK Consensus Group.
Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston S, Reeve J, Reid DM, Russell RG, Stevenson JC. Eastell R, et al. QJM. 1998 Feb;91(2):71-92. doi: 10.1093/qjmed/91.2.71. QJM. 1998. PMID: 9578891 Review.
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.
Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE; Joint IOF-ECTS GIO Guidelines Working Group. Lekamwasam S, et al. Among authors: eastell r. Osteoporos Int. 2012 Sep;23(9):2257-76. doi: 10.1007/s00198-012-1958-1. Epub 2012 Mar 21. Osteoporos Int. 2012. PMID: 22434203 Review.
An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.
Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Perez AD, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE; Joint IOF–ECTS GIO Guidelines Working Group. Lekamwasam S, et al. Among authors: eastell r. Arch Osteoporos. 2012;7:25-30. doi: 10.1007/s11657-012-0070-7. Epub 2012 Mar 21. Arch Osteoporos. 2012. PMID: 23225278
634 results